Skip to content

Stempoint Capital LP 13F Holdings · Q2 2026

Stempoint Capital LP reported 73 securities worth $580.52M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: TNGX (6.62%), ABVX (6.51%), RVMD (5.18%). Among its top 25 positions this quarter: 4 new, 11 added, 10 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1TNGXTANGO THERAPEUTICS INC$38.4M6.62%1.3MAdded
2ABVXABIVAX SA$37.8M6.51%283,657Trimmed
3RVMDREVOLUTION MEDICINES INC$30.1M5.18%189,943Trimmed
4ERASERASCA INC$28.8M4.96%1.8MAdded
5TYRATYRA BIOSCIENCES INC$20.2M3.48%632,754Added
6DNTHDIANTHUS THERAPEUTICS INC$19.6M3.37%200,851Added
7ELVNENLIVEN THERAPEUTICS INC$17.6M3.03%346,914Trimmed
8BHVNBIOHAVEN LTD$16.4M2.82%1.6MTrimmed
9MLYSMINERALYS THERAPEUTICS INC$16.3M2.80%602,686Added
10SRZNSURROZEN INC$13.8M2.37%602,798Trimmed
11KNSAKINIKSA PHARMACEUTICALS INTL$13.4M2.30%209,234New
12SRRKSCHOLAR ROCK HLDG CORP$13.2M2.27%239,146Trimmed
13ALKSALKERMES PLC$13.0M2.24%248,015Added
14TRAXFIRST TRACKS BIOTHERAPEUTICS$12.5M2.16%622,723New
15PRAXPRAXIS PRECISION MEDICINES I$12.5M2.15%37,243Trimmed
16ROIVROIVANT SCIENCES LTD$12.4M2.13%448,408Added
17BIOABIOAGE LABS INC$11.4M1.96%464,171Added
18CGONCG ONCOLOGY INC$11.3M1.95%159,349Trimmed
19ORKAORUKA THERAPEUTICS INC$11.1M1.91%116,461New
20IMVTIMMUNOVANT INC$10.7M1.84%276,527Trimmed
21CELCCELCUITY INC$10.3M1.77%98,203Added
22RLMDRELMADA THERAPEUTICS INC$10.1M1.74%1.5MAdded
23CLYMCLIMB BIO INC$9.7M1.67%742,745New
24SYRESPYRE THERAPEUTICS INC$9.5M1.64%106,926Trimmed
25ZURAZURA BIO LTD$8.1M1.39%1.4MAdded

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR